Regulatory T cells (Tregs) in liver fibrosis
Open accessThe DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Abstract
The ability of the human liver to both synthesize extracellular matrix(ECM), as well as regulate fibrogenesis, are integral functions to maintaining homoeostasis. Chronic liver injury stimulates fibrogenesis in response to the imbalance between ECM accumulation and fibrosis resolution. Liver disease that induces fibrogenesis is associated with multiple risk factors like hepatitis infection, schistosomiasis, alcohol, certain drugs, toxicants and emerging aetiology like diabetes and obesity. The activation of hepatic stellate cells (HSCs), whose function is to generate and accumulate ECM, is a pivotal event in liver fibrosis. Simultaneously, HSCs selectively promote regulatory T-cells (Tregs) in an interleukin-2–dependent pattern that displays a dual relationship. On the one hand, Tregs can protect HSCs from NK cell attack, while on the other hand, they demonstrate an inhibitory effect on HSCs. This paper reviews the dual role of Tregs in liver fibrogenesis which includes its promotion of immunosuppression, as well as its activation of fibrosis. In particular, the balance between Tregs and the Th17 cell population, which produce interleukin (IL)-17 and IL-22, is explored to demonstrate their key role in maintaining homoeostasis and immunoregulation. The contradictory roles of Tregs in liver fibrosis in different immune microenvironments and molecular pathways need to be better understood if they are to be deployed to manage this disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bataller, R., & Brenner, D. A. (2005) · Journal of Clinical Investigation · doi:10.1172/jci24282 · Cited by 4,958
Differentiation of Effector CD4 T Cell Populations
Zhu, J., Yamane, H., & Paul, W. E. (2010) · Annual Review of Immunology · doi:10.1146/annurev-immunol-030409-101212 · Cited by 3,452 · cited 1×
“Recent advances in immunology have focused on two new T cell subsets (Treg and Th17 cells) that supplement and refine the classical theory of Th1/Th2 [83] interplay.”
BackgroundMechanisms of hepatic stellate cell activation
Tsuchida, T., & Friedman, S. L. (2017) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2017.38 · Cited by 2,909
Hepatic Stellate Cells: Protean, Multifunctional, and Enigmatic Cells of the Liver
Friedman, S. L. (2008) · Physiological Reviews · doi:10.1152/physrev.00013.2007 · Cited by 2,842 · cited 13×
“MMPs, the main enzyme involved in ECM degradation [28] are produced primarily by KCs [29], however, even a low ratio of Tregs can repress KC expression of MMPs. Treg cells regulate the balance of MMP/TIMP through KCs, thereby inhibiting the resolution of fibrosis [4] [Fig.”
BackgroundInfluentialMiyara, M., Yoshioka, Y., Kitoh, A., Shima, T., Wing, K., Niwa, A., Parizot, C., Taflin, C., Heike, T., Valeyre, D., et al. (2009) · Immunity · doi:10.1016/j.immuni.2009.03.019 · Cited by 2,291
Takahashi, T., Tagami, T., Yamazaki, S., Uede, T., Shimizu, J., Sakaguchi, N., Mak, T. W., & Sakaguchi, S. (2000) · The Journal of Experimental Medicine · doi:10.1084/jem.192.2.303 · Cited by 2,233
Molecular and cellular mechanisms of liver fibrosis and its regression
Kisseleva, T., & Brenner, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-020-00372-7 · Cited by 2,024 · cited 1×
“Non-resolving liver fibrogenesis, stimulated by a wide range of risk factors, induces the activation of quiescent hepatic stellate cells (HSCs) into myofibroblasts that are the primary extracellular matrix (ECM)-cell type that promotes fibrous protein deposition and scarring [2].”
BackgroundPathogenesis of Liver Fibrosis
Hernandez-Gea, V., & Friedman, S. L. (2011) · Annual Review of Pathology: Mechanisms of Disease · doi:10.1146/annurev-pathol-011110-130246 · Cited by 1,809 · cited 2×
“In patients suffering from chronic liver injury, progression to the end stage usually takes 20 to 40 years depending on whether both environmental and genetic elements are causal factors [1].”
BackgroundLiver fibrosis – from bench to bedside
Friedman, S. L. (2003) · Journal of Hepatology · doi:10.1016/s0168-8278(02)00429-4 · Cited by 1,780 · cited 1×
“Chronic hepatitis infection, for instance, promotes liver fibrosis that can translate into cirrhosis and the onset of neoplasms (Chronic hepatitis→ liver fibrosis→ liver cirrhosis→ Liver Neoplasms) [3].”
BackgroundPlasticity of CD4+ T Cell Lineage Differentiation
Zhou, L., Chong, M. M. W., & Littman, D. R. (2009) · Immunity · doi:10.1016/j.immuni.2009.05.001 · Cited by 1,551 · cited 1×
“3], while Th17 cells can be transformed into Th1/2 cells in the existence of IL-4 or IL-12 [81].”
Background
Cited by
Immunoregulation of Liver Fibrosis: New Opportunities for Antifibrotic Therapy
(2024) · doi:10.1146/annurev-pharmtox-020524-012013 · Cited by 64
Amelioration of liver fibrosis with autologous macrophages induced by IL-34-based condition
Igarashi, Y., Wada, H., Muto, M., Sone, R., Hasegawa, Y., & Seino, K.-I. (2025) · Inflammation and Regeneration · doi:10.1186/s41232-025-00364-7 · Cited by 5
Jin, H., Zhong, X., Zhang, C., Wu, Y., Sun, J., Wang, X., Wang, Z., Zhu, J., Jiang, Y., Du, X., et al. (2025) · Molecular Metabolism · doi:10.1016/j.molmet.2025.102131 · Cited by 2
Metadata
- Authors
- Wu, K.-J., Qian, Q.-F., Zhou, J.-R., Sun, D.-L., Duan, Y.-F., Zhu, X., Sartorius, K., & Lu, Y.-J.
- Venue
- Cell Death Discovery
- Published
- 2023-02-09
- Volume
- 9
- Issue
- 1
- Pages
- 53-53
- ISSN
- 2058-7716 (ISSN-L)
- OpenAlex
- W4319825957
- Cited by
- 83
- References
- 22
- FWCI
- 11.75
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Regulatory T cells (Tregs) in liver fibrosis. https://app.cochat.ai/papers/10.1038/s41420-023-01347-8
- The paper
- Wu, K.-J., Qian, Q.-F., Zhou, J.-R., Sun, D.-L., Duan, Y.-F., Zhu, X., Sartorius, K., & Lu, Y.-J. (2023). Regulatory T cells (Tregs) in liver fibrosis. Cell Death Discovery. https://doi.org/10.1038/s41420-023-01347-8
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.